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Simple Summary: The rate of death and disease in young dairy calves is alarmingly high, with
diarrhea accounting for over half of all disease incidence. The majority of diarrhea cases are treated
with antimicrobials, which may not be warranted. There is increasing concern related to the use
of antimicrobials in food animals due to the emanant development of antimicrobial resistance.
Bovine colostrum is densely packed with hundreds of nutrients and bioactives specifically tailored
to improve calf health and development. As such, colostrum may have potential to be used an
alternative to antimicrobials for the treatment of diarrhea. The objective of this review is to outline the
causation and implication of diarrhea in young dairy calves and to explore the benefits of colostrum
and its potential use as a therapy and preventative for diarrhea in pre-weaned calves.
Abstract: Diarrhea is the leading cause of morbidity and mortality in pre-weaned dairy calves and,
as such, represents a significant animal health and welfare concern. Furthermore, digestive disease
early in life is associated with several long-term consequences such as reduced growth rate and
decreased milk yield during the first lactation, thus generating severe economic losses. The majority
of diarrheic cases in young calves are treated with antimicrobials; however, it is necessary to develop
alternative treatments, as excessive antimicrobial usage can lead to antimicrobial resistance and
can negatively impact the gut microflora of a calf. Bovine colostrum is abundant in immune and
bioactive factors that improve immune function and development. This rich and natural combination
of immunoglobulins, natural antimicrobial factors, growth factors, anti-inflammatories and nutrients
may be an attractive alternative to antimicrobials in the treatment of diarrhea in young dairy calves.
There is evidence that supports the use of colostrum as an early treatment for diarrhea in young
calves. Future research should investigate its therapeutic and economic effectiveness.
Keywords: calf; diarrhea; colostrum; preventative; therapy
1. Introduction
High levels of disease in dairy calves threaten the economic efficiency and sustainabil-
ity of the global dairy industry. Recent reports state that digestive diseases (i.e., diarrhea)
are the leading cause of disease and death in the pre-weaning period [1]. Specifically,
digestive disease accounts for 56% and 32% of morbidity and mortality, respectively [1],
with the highest incidence in the second week of life [1–3]. Diarrhea is a multifactorial
disease that results from a combination of exposure to pathogens, the environment and the
host’s immune system [4]. The most common diarrheic pathogens include rotavirus and
coronavirus, Cryptosporidium parvum (C. parvum), Enterotoxigenic Escherichia coli (E. coli),
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Clostridium perfringens and Salmonella spp. [3,5,6], most of which are highly contagious [7].
Exposure to one or more of these pathogens may result in diarrhea, which can be further
exacerbated by a compromised immune system that may be a result of other diseases and
poor management [8]. It is clear that the high incidence of diarrhea in young calves poses a
significant concern from both welfare and health standpoints. Yet, diarrhea in pre-weaned
calves can also have long-lasting economic effects [3], including a reduction in average
daily gain (ADG) [9–11], an increased number of inseminations to achieve first pregnancy
and an over 300 kg decrease in milk yield during the first lactation [11]. Consequently,
research focusing on diarrhea therapy and prevention in young dairy calves is vital to the
profitability of the dairy industry.
The majority of gastrointestinal diseases in calves are treated with antimicrobials [7].
Specifically, a study conducted in the United States found that 33.9% of all dairy calves were
administered antimicrobials, with 75% of dairy calves with diarrhea receiving antimicrobial
therapy [1]. There are a number of production, societal and health concerns pertaining to
the frequent and improper use of antimicrobials in food production animals, including
an increased risk of antimicrobial resistance [12]. Furthermore, animals administered
antimicrobials, particularly young animals, can be negatively impacted by alterations to
the gut microbiota in early life [13]. The diversity and abundance of total commensal gut
microbiota can be reduced alongside targeted pathogens, upsetting microbial balance and
causing gastrointestinal tract (GIT) dysfunction [14,15]. Due to the potential detrimental
effects of high rates of antimicrobial administration, efforts should be made to reduce
their use. Thus, the investigation of efficient alternatives to antimicrobials is necessary to
improve both calf health and welfare, as well as consumer trust of the dairy industry and
its products.
Bovine colostrum is densely packed with bioactive factors (i.e., antibodies, hormones
and growth factors) and nutrients, resulting in a composition that differs substantially
from mature milk [16]. Colostrum’s beneficial qualities have been used for centuries to
provide several species with supplemental nutrition and treatment for numerous illnesses,
including diarrhea in humans [17–26]. More recently, the advantages of colostrum as a
prophylactic and therapeutic in young calves has been explored [27–30]. This research
exemplifies that beneficial bioactives within bovine colostrum may provide an effective
therapeutic alternative to antimicrobials for treatment of diarrhea in calves. Most research in
this field involves the use of hyperimmune colostrum which is created by exposing the dam
to specific pathogens, thus enriching her colostrum with pathogen specific antibodies [17].
This form of therapy can be expensive and lacks efficiency compared to natural bovine
colostrum [17,31]; however, evidence supporting the use of natural colostrum as a therapy
for diseases in cattle is lacking. Thus, the objective of this narrative review is to evaluate the
physiology and effects of neonatal gastrointestinal diseases in dairy calves and, importantly,
explore the potential benefits of colostrum as a prophylactic and therapeutic for neonatal
calf diarrhea.
2. Causation of Digestive Disorders in Neonatal Calves
The dairy industry has made tremendous efforts to improve animal housing, hygiene,
nutrition and health. However, neonatal calf diarrhea is still a major concern due to its mul-
tifactorial nature. As mentioned previously, digestive disorders can be a consequence of the
environment, immunosuppression, pathogenic factors or a combination of the three [32,33].
Common diarrhea-causing pathogens include rotavirus and coronavirus (viral), C. parvum
(protozoa), E. coli, Clostridium perfringens and Salmonella spp. (bacteria) [3,5,34]. E. coli,
C. parvum and rotavirus have been found to cause >70%, >55% and 80% of cases of enteric
illnesses in calves, respectively [2,3,5,35]. In addition, recent studies have demonstrated
an increased frequency of multi-pathogen illnesses, with rotavirus and C. parvum being
the most common pathogen combination [4,34]. An Australian study, which tested ap-
proximately 600 calves with diarrhea from 84 dairy and dairy beef farms, found that 96.4%
of farms and 71% of samples contained multiple pathogens. In the infected calves, 42.8,
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39.5 and 35.5% of samples contained two, three and four pathogens, respectively [5]. While
pathogens can have synergistic and antagonistic effects on one another [3], evidence sug-
gests that the difference between single pathogen and multi-pathogen diarrhea could be
subclinical and clinical, respectively [4].
Although pathogens are associated with diarrhea, they can also be present in healthy
calves. It has been determined that bovine coronavirus and rotavirus, as well as C. parvum,
can be present in a calf without causing severe diarrhea [36]. Other factors, including failed
transfer of passive immunity, poor nutrition, unhygienic conditions, hostile environmental
conditions and poor management, can decrease immune function, allowing pathogens
to thrive and ultimately cause neonatal calf diarrhea [5,6,8,35]. Specifically, routine and
frequent cleaning of calf and maternity pens significantly decreases the risk of diarrhea [37].
Additionally, limiting other illnesses such as respiratory disease will reduce the risk of
diarrhea caused by invasion of opportunistic pathogens [3,37]. Due to the aggressive
nature of many diarrhea-causing pathogens, symptoms can be long-lasting and result in
long-term consequences.
Diarrhea is a result of decreased absorption and increased secretions of water and
electrolytes in the gut. This process generally begins with the ingestion of a single or
multiple pathogens, which initiates numerous pathogenic physiological pathways leading
to severe dehydration [33,38,39]. Consequently, the loss of fluids can cause a multitude
of health and behavioral issues, including aversion to suckling, anorexia, depression,
weakness and, in severe cases, death [7,33,38].
Rotavirus, coronavirus and C. parvum similarly cause villous atrophy by target-
ing small intestinal crypts that house stem cells that stimulate enterocyte renewal, see
Figure 1 [38–40]. While rotavirus replicates in the cytoplasm of the epithelial cells in the
small intestinal villi, coronavirus is released through cell lysis once replication is completed
in enterocytes [38]. Rotavirus causes destruction to mature cells in the villi and activates
non-structural glycoprotein 4, an enterotoxin that stimulates an influx of calcium ions,
resulting in enterocyte destruction [41]. The pathophysiology of coronavirus is similar
to rotavirus; however, this enveloped virus uses a spike protein to bind and fuse to the
membrane of the host enterocyte, leading to atrophy [38]. C. parvum replicates through
sexual and asexual reproduction, which creates autoinfecting thin-walled oocytes. The in-
vasion results in atrophy of columnar epithelial cells and a loss of microvilli [38]. Salmonella
destroys enterocytes by invading the intestinal mucosal layer, and continues to multiply in
the lymphoid tissues [42]. The bacteria will then circulate through the body from mesen-
teric lymph nodes, initiating systemic illness [38,43]. Enterotoxigenic E. coli is another
bacterium that is a major cause of diarrhea in calves. These bacteria attach to the immature
epithelium through fimbria adhesion, mainly in the distal portion of the small intestine due
to a favorably low pH. Hypersecretory diarrhea and dehydration results from the release of
excess electrolytes and water due to villous atrophy though laminar propria damage and
the release of thermo-stable toxins see Figure 1 [38]. Additionally, after enterocyte invasion,
Clostridium perfringens may cause changes to the structure of the intestinal cytoskeleton
through shortening of the columnar epithelial cells and destruction of microvilli due to
necrotizing enteritis [38]. If not monitored and treated promptly, any of these pathogens
can cause severe dehydration, malnutrition, reduced growth and death.
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Figure 1. Pathophysiology of diarrhea-causing pathogens; rotavirus, coronavirus, C. parvum and E. coli.
Consequences, Concerns and the Economic Loss of Neonatal Calf Diarrhea
Diarrhea in pre-weaned calves can have a direct economic impact on producers
through treatment and labor costs. Specifically, Goodell et al. (2012) calculated that a
case of diarrhea in a pre-weaned calf costs USD 56, due to the cost of increased labor and
medication. Beyond these costs, pre-weaning calf diarrhea carries a 5.1% case fatality
rate [44]. Diarrhea in the pre-weaning period can also have long lasting effects, as it
negatively impacts ADG by 50 g/day [11,32], and results in almost a 10% reduction in
milk yield during first lactation [11,45]. In addition, calves with diarrhea are 2.9 times
more likely to achieve first calving after 30 months of life [46]—six months later than
optimal calving age [47]. A later age at first calving can lead to decreased lifetime milk
production and increased costs to rear replacement animals [45]. Additionally, late calving
age is associated with a higher weight at first calving, causing considerable metabolic and
production complications during the transition period and throughout lactation [48]. It
is clear that the negative impacts of pre-weaning diarrhea can have not only short-term
consequences on calf health, but long-term effects on cow physiology and milk production.
Thus, it is important to investigate strategies that reduce the high incidence of diarrhea, as
well as potential alternatives to antimicrobials when clinical diarrhea occurs.
Aside from its economic impacts, pre-weani diarrhea poses a major threat to calf
welf r . There are myriad negative welfare challenges associated ith diarrhea for pre-
weaned calves, such as ataxia, dehydration through loss of fluids nd weakness [49].
Furthermore, due to its immunosuppressiv nature, calve with diarrhea have a higher
likeliho d of contracting other illnes es, such as re pira ory disease [38]. Additionally,
several symptoms caused by di rrhea ay result in unnecessary stress and pain c used
by an r xia and dehydration, whic may ultimately result in de th [3,50]. Furthermore,
certain pa hogens associated with calf diarrhea (Cryptosporidium, rotavirus and Salmonella)
can be har ful to human h alt due to their zoonotic potential, as well as their abili-
ties to develop antimicrobial resistance which can be passed on when meat and milk is
consumed [6,42,51–54].
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3. Antimicrobial Usage and Its Role in Diarrhea Therapy
Amoxicillin, chlortetracycline, neomycin, oxytetracycline, streptomycin, sulfachloropy-
ridazine, sulfamethazine and tetracycline are all currently labeled in the United States
for the treatment of calf diarrhea [7]. According to Urie et al. (2018), the antimicrobials
listed above are utilized as a therapy for approximately 75% of calves diagnosed with
diarrhea during the pre-weaning period. Due to a heavy reliance on these antimicrobials,
pathogens such as E. coli and Salmonella have developed resistance to antimicrobials [55,56].
In addition, antimicrobial exposure can weaken the host’s immune system, increasing the
risk for opportunistic pathogens, such as coronavirus, to colonize the gut [3]. Antimicro-
bial therapy is meant to target specific pathogens; however, this tends to force the gut
microbiota into dysbiosis [14,15] through negatively impacting similar indigenous gut
microbiota that play an important role in digestion and immunity [13,57]. The modification
and deterioration of the composition of the gut microflora can lead to long-lasting negative
effects [58], including increased gut permeability that allows for increased invasion of
numerous pathogens [59]. Recent research in mice has shown that altered gut microflora
composition negatively affects macrophage functions by pushing them into a hyperactive
state [55], resulting in T-cell dysfunction and, ultimately, increased susceptibility to dis-
ease [55]. The pre-weaning period is a vital stage in gut microbiota establishment [56].
Disruption of gut microbial homeostasis during this period can have detrimental effects
on calf health, including increased sensitivity to enteric infection, systemic disease and
autoimmune disorders [58]. Due to the negative implications of antimicrobial use on the
host immune system and gut microbiome, as well as concerns relating to the emergence of
antimicrobial resistance, there is a push for producers to reduce heavy reliance on antimi-
crobials and begin to source alternatives when treating and augmenting the production
and growth of their animals in order to ensure social acceptance by the dairy industry [60].
4. The Role of the Gastrointestinal Microbiome in Maintaining Gut Homeostasis
An infant’s gut is sterile in utero, with gut microbiome colonization beginning at
parturition and continuing through early life [61]. A similar process is suspected in the
calf [61]; however, there is evidence that suggests microbiota development may begin
prenatally [62]. Although diversity of the gut microflora is marginal at birth [63], during
the first 48 h of life and beyond, the microbiome is highly variable and diversifies signifi-
cantly [64]. With much of the gut microbiota colonization occurring through environmental
interactions at and soon after birth [65], colostrum feeding in early life can also significantly
influence and shape a calf’s microbiome due to its ample supply of energy sources which
are provided to the gut bacteria [65,66]. Rectal microbiota samples from newborn calves at
birth show composition of Firmicutes, Proteobacteria, Actinobacteria and Bacteroidetes
(phyla) [64]. However, by the first day of life, significant changes occur and only Firmicutes
and Bacteroidetes remain, which is mainly a result of the environmental microbiota and
colostrum feeding [64]. In the pre-weaning period, the intestinal microbiome is mainly
comprised of bacteria [67,68] with Lactobacillus, Corynebacterium, Streptococcus, clostridium,
Pepto streptococcus and Bifidobacterium being among the 167 genera identified at one week
of life in the intestinal tract [67,68]. The gut microbiome changes significantly and continu-
ously as the calf develops, consumes more solid feed and is weaned off milk [67].
The gut microbiota plays an important role in stimulating the function of the host
immune system. This is especially prominent in neonates, where the early interactions
of microbial communities can initiate long term immunity through the development of
the mucosal layer of the epithelial cell barrier [69–71]. The epithelial layer is necessary for
many vital immune and digestive functions of the GIT, where it plays a role in nutrient
absorption and facilitates microbial cross-talk, as well as acts as a barrier against bacterial
invasion [13,71,72]. Bacteria in the gut have a plethora of other functions, including im-
proving immune function, decreasing pH, mucosal gut barrier maintenance and increasing
digestive capacity [73]. The gut itself provides a localized immune response by eliminating
pathogens with antigen presenting cells, neutrophils and natural killer cells [74]. Addition-
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ally, a large proportion of T-cells are present in the GIT, which are critical in the defense
against pathogens [74]. The colonization of commensal microbes and their subsequent
effects on calf immunity during early life promote a healthy gut environment, which may
provide protection against pathogens and the high incidence of diarrhea in young calves.
5. Colostrum
Colostrum, the first milk produced following parturition, functions to aid in promot-
ing growth and development of the neonatal calf, but it also supplies maternal antibodies
and cell-mediated immunity to stimulate immune function within the first hours of life
See Table 1 [2]. On-farm colostrum management has the greatest association with calf
morbidity and mortality [75]; thus, it is vital to monitor the quality, quantity and clean-
liness of colostrum and to ensure the calf receives the first colostrum feeding in a timely
manner [76,77]. To be characterized as “good-quality”, colostrum should contain > 50 g/L
of immunoglobulin G (IgG) to ensure successful transfer of passive immunity [77]. Quality
can be altered by many factors, such as breed and age of the dam, season of calving, length
of previous lactation and delayed colostrum collection [77]. Additionally, nutrition and
health during the periparturient period of the dam such as energy and length of the dry
period have shown to affect colostrum IgG levels [78]. In terms of quantity, calves should
receive 10–12% of their body weight in colostrum at their first feeding, which over 50%
of Canadian producers achieve [77,79], and ensure consumption of at least 150–200 g
of IgG during the first 24 h of life [77,80]. Due to gut closure occurring during the first
day of life, it is vital that colostrum is fed soon after birth to supply the calf with ample
immunoglobulins [76]. Additionally, the cleanliness of colostrum is crucial to calf vitality.
The method in which colostrum is collected and stored can influence the calf’s metabolism,
endocrine system and nutrition [19,81]. The majority of Canadian dairy farmers reported
that they regularly remove calves from the calving pen within 30 min after birth and
prohibit suckling from the dam [79]. If contamination with bacteria occurs during the
collection process, bacteria can bind to immunoglobulins, inhibiting their transport across
the enterocytes and thus reducing transfer of passive immunity [77].
Bovine colostrum is abundant in immunoglobulins, which are more than 100 times
greater in colostrum than mature milk, to ensure protection against disease [16]. The
common isotopes include immunoglobulin M (IgM), immunoglobulin A (IgA) and IgG,
of which IgG is the primary isotope [2] accounting for 85–90% of all bovine colostral
immunoglobulins [82]. Immunoglobulins are composed of short and long polypeptide
chains, with each class and sub-class differing slightly in chain formation [82].
During the first 24 h of life, maternal immunoglobulins are absorbed through colostrum
to provide passive immunity to the calf [76]. After ingestion, immunoglobulins transfer
into the neonate’s circulatory system through the lumen of the small intestine [16], where
the calf is provided with short-term, immediate immunity [83]. As gut permeability de-
creases rapidly during the first day of life [84], delaying colostrum intake to as late as
12 h of life will concurrently reduce passive transfer of immunoglobulins [85]. Prior to
absorption, immunoglobulins will also defend against disease, binding to pathogens on
antigen binding sites of the intestinal mucosal membrane and thus preventing further intru-
sion or adhesion to the epithelium through the provision of an intestinal barrier [17,86,87].
Colostrum also contains compounds that are responsible for the protection of immunoglob-
ulins, such as trypsin inhibitor, which is 100 times more abundant in colostrum. This
prevents degradation of IgG in the GIT, thus increasing the availability of IgG for the
calf [77].
In addition to the supply of immunoglobulins in colostrum, the latter contains an
abundance of antimicrobial components. Lactoferrin, a bioactive protein in colostrum, has
been shown to prevent sepsis in infants and calves, which can occur in calves with diar-
rhea [88,89]. It exhibits antimicrobial characteristics by creating a localized iron deficiency
in bacteria though its binding capabilities, thus minimizing the potential for bacterial
growth [16]. Moreover, it inhibits the growth of many microbes, including E. coli and
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Salmonella [90–93]. Lactoperoxidase is a similar bioactive compound that exhibits antimi-
crobial qualities by inhibiting bacterial metabolism through the suppression of oxidation
in protein groups [16]. Another bioactive compound, lysozyme, can actively protect the
host from Gram-positive and Gram-negative strains of bacteria by hydrolyzing the β
1–4 linkages in the cell wall, thus causing cell lysis [16,94].
Colostrum is also rich in additional bioactive molecules [95,96], such as insulin, insulin-
like growth factor-I (IGF-I) and IGF-II [96]. Following parturition, their concentrations
decline rapidly; therefore, early collection of colostrum is vital to ensure that the concentra-
tions of both IgG and bioactive molecules are not diluted by transition milk [96]. Insulin
has been shown to improve the oral glucose absorption capabilities of the calf, thus increas-
ing its electrolyte levels [97]. Growth factors have been shown to stimulate the growth
and maturation of the intestines, as well as the other mammalian cells [16]. Specifically,
epithelial cell growth and development is stimulated by IGF-I and IGF-II [16]. Similarly,
colostrum is rich in additional bioactive factors related to the innate and acquired immune
system that are useful in the treatment and prevention of certain illnesses [98]. These in-
clude neutrophils, macrophages, immune regulators and anti-inflammatory molecules [98].
Neutrophils and macrophages are responsible for eliminating pathogens directly through
phagocytosis, as well as through the production of cytokines [98]. Cytokines, including
IL-1β, IL-6, TNF-α and INF-γ, regulate immune function, infection and stress though
immune cell recruitment, meditation of inflammatory processes, enhancing phagocytotic
abilities and immunological maturation [18,99]. In addition to factors that provide direct an-
timicrobial support with endotoxin-neutralizing abilities, colostrum contains several more
bioactive molecules such as leptin, casein and α-lactalbumin that can reduce gut inflamma-
tion to encourage tissue repair and improve gastrointestinal mucosal integrity [18,100].
Although the concentrations of colostral components can vary, colostrum typically
contains less than half the amount of lactose and more than 70% of oligosaccharides found
in whole milk [101]. High levels of sialylated oligosaccharides are beneficial, as they
have many potential prophylactic functions [101,102]. During a disease state, oligosac-
charides provide several benefits through the inhibition of the binding capacity of certain
pathogens, including E. coli and rotavirus, to the intestinal epithelium [102–106] and
through the reduction in gut permeability by enhancing the expression of lipoproteins
that comprise the tight junctional complexes [105,106]. Furthermore, oligosaccharides also
decrease intestinal inflammation by reducing the expression of pro-inflammatory cytokines,
which modulate proteins in epithelial tight junctions and enhance the expression of anti-
inflammatory cytokines [105,106]. In addition, certain oligosaccharides may accelerate and
improve the development of gut microflora in the calf by acting as an energy source for
bacteria [104–107].
Overall, the fat content of colostrum is higher than that of transition or mature
milk [95]. Elevated concentrations of certain fatty acids in colostrum insinuates that
lipids may be essential for neonatal calves [108]. Neonatal ruminants are born with low
energy stores and a limited ability to thermoregulate [109], as only 3% of a calf’s body
weight is made up of lipids at birth [110]. The high levels of fat in colostrum are necessary
to provide energy and to improve the calf’s thermoregulatory abilities [109]. Moreover,
parturition activates the calf’s metabolic and respiratory processes, exposing it to high
levels of oxidative stress [111]. Although the majority of lipids are in the form of triglyc-
erides [112], the increased concentration of polyunsaturated fatty acids in colostrum has
been shown to reduce the numbers of oxidants and reactive oxygen and nitrogen species,
providing a greater antioxidant capacity and decreasing oxidative stress experienced by
the calf [111,113].
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Table 1. Benefits to gut immunity and development provided by colostrum components.
Colostrum Bioactive
Concentration Benefit to the Gastrointestinal Tract Reference
Unit Colostrum Mature Milk
Immunoglobulin G g/L 81 <2
Primary immunity contributor
through pathogen binding in the
intestinal mucosal membrane and
passive immunity when absorbed into
the circulatory system.
[17,77,86,87,96]
Lactoferrin g/L 1.84 0.1
Sepsis prevention in infants. Binds to
iron, preventing excess growth of
bacteria, such as E. coli and Salmonella.
[16,88–93,96,114]
Lactoperoxidase g/L 0.011–0.045 0.013–0.030
Inhibitory effects on bacterial
metabolism through suppression of
oxidation in proteins.
[16,114]
Lysozyme µg/L 140–700 70–600
Cell lysis caused by hydrolysis of β




Insulin µg/L 65 1 Promotes cell growth in thesmall intestine. [96,115]
Insulin-like growth factor-I µg/L 310 <2 Stimulates intestinal cell growth andepithelial development. [16,96]
Insulin-like growth factor-II µg/L 150 1 Stimulates intestinal cell growth andepithelial development. [16,96,116]
Oligosaccharides g/L 1 <0.2 Reduces gut permeability andpromotes gut microflora development. [101,117]
Fatty Acids g/L 64 39
Improves thermoregulation
capabilities. High levels of PUFA
decreases oxidative stress by reducing


















through the neutralization of
pro-inflammatory molecules.
Specifically, INF-γ amplifies the
capacity of phagocytic cells.
[99,118]
5.1. Hyperimmune Colostrum as a Treatment for Diarrhea
Hyperimmune colostrum has been used as a therapy for gastrointestinal diseases in
the dairy industry for many years [17]. It is produced by exposing the dam to a specific
pathogen, which will enrich her colostrum with IgG specialized to recognize and protect
the neonate against the specific pathogen in question [17,119]. This antibody-enriched
colostrum has been used in human infants, children and adults to treat diarrhea caused by
coronavirus [21], rotavirus [23] and C. parvum, alleviating symptoms for up to 3 months
at a time with a single dose [22,24,25]. Hyperimmune colostrum has also shown to be
effective in reducing the concentration C. parvum in the GIT of mice [120] and decreasing
calf mortality during a coronavirus challenge [21]. Treating gastrointestinal diseases with
hyperimmune colostrum is an attractive alternative to antimicrobials, as there are no effects
on the diversity of the gut microflora [121]. Although hyperimmune colostrum poses
several benefits, it is not feasible on a mass scale for treatment of calf diarrhea due to cost
and production time. The use of hyperimmune colostrum may also pose societal concerns
from both cow welfare and health standpoints due to the purposive administration of
pathogens to create a product for the animal production industry. Furthermore, as stated
previously, calf diarrhea is a multifactorial disease, and a single case of diarrhea can be
caused by multiple pathogens. Thus, it would prove increasingly difficult and expensive
to expose cows to multiple pathogens to create a hyperimmune colostrum that is effective
towards the abundance of pathogens implicated in calf diarrhea. When the inefficiency and
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potential welfare and health concerns of hyperimmune colostrum are considered, it is clear
that natural colostrum may act as a more suitable option to prevent and treat calf diarrhea.
5.2. Natural Colostrum as a Preventative for Calf Disease
Failure to absorb an adequate quantity of high quality immunoglobulins, especially
IgG, is termed failed transfer of passive immunity, which results in a deficient immune
system and increased risk of disease [76]. A newly recommended scale has been designed
to measure transfer of passive immunity in four categories: >20.5, 18.0–24.9, 10–17.9 and
<10 IgG/L representing excellent, good, fair and poor, respectively [122]. Achievement of
good and excellent rates of passive transfer are used as a metric to indicate a lower risk for,
and less susceptibility to, morbidity and mortality [122]. Although correlations between
morbidity and mortality and the newly recommended passive transfer categories have
been clearly demonstrated, it is necessary to determine correlations between each category
and the incidence of specific diseases, including both respiratory and digestive disease.
Recently, there have been several studies highlighting the benefit of prolonged supple-
mentation of colostrum beyond the first day of life. Kargar et al. (2020) determined that the
enhancement of five liters of milk replacer with 0.7 kg/day of colostrum for 14 days postna-
tally improved ADG and decreased the risk of elevated rectal temperatures, diarrhea and
pneumonia. Likewise, Berge et al. (2009) concluded that enhancing milk replacer with 70 g
of colostrum replacer for 14 days increased grain consumption and ADG while reducing
diarrhea incidence and antimicrobial administration. In addition to improved health, transi-
tion milk has also been shown to improve the development of the gastrointestinal tract [19].
Feeding colostrum for 72 h postnatally has been shown to improve the development and
maturation of the small intestine, as well as improve IgG persistency [123,124]. Similarly,
an enhanced nutritional plane in the pre-weaning period results in improved mammary
tissue growth and mammogenic stimulation [125]. However, it is difficult to distinguish
whether the benefits of the majority of the aforementioned studies are a result of extra
nutrients, bioactives or a combination of the two, as energy and protein provisions are
rarely balanced between treatments. Yet, this collection of studies suggests that an elevated
colostrum allowance following the first day of life improves calf health and development,
thus acting as a short- and long-term prophylactic for disease. Specifically, this research,
along with the current body of literature highlighting the beneficial effects of colostral
bioactive molecules on calf GIT development and health, indicate the great potential for
colostrum as a preventative treatment for the current high rates of calf diarrhea.
5.3. Natural Colostrum as a Treatment for Diarrhea
Studies evaluating the use of natural colostrum have also shown positive results when
using it as a treatment for different forms of diseases in humans. Bovine colostrum has
been shown to improve gut immunity following certain diseases or treatments, such as
short term bowel syndrome and chronic pain syndrome [18]. It has been found to minimize
the immunosuppressive effects of intense physical activity through enhanced recovery
and improved immune response [126]. Moreover, owing to the antimicrobial and anti-
inflammatory properties of bovine colostrum, it can be beneficial in treating many different
infections [18].
Few studies have explored the efficacy of bovine colostrum as a treatment for disease
in neonatal calves. Cantor et al. (2021) highlighted how the use of colostrum may reduce
disease likelihood in calves that had shown early disease symptoms. This research exempli-
fies that colostrum has an advantageous influence on calves displaying signs of morbidity;
however, further research must investigate the effects of colostrum on diarrhea specifically.
Bovine colostrum holds the potential to become a sustainable and effective therapy for
neonatal calf diarrhea [127]. Colostrum has shown to naturally improve development and
microbial colonization and development, as well as minimize inflammation within the
GIT [66,77]. Critically high levels of antimicrobial resistance, in addition to the physiologi-
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cal upset antimicrobials pose to a young calves’ GIT, warrant a shift in therapeutics used
for the treatment of diarrhea in pre-weaning calves [14,55,56].
Feeding colostrum after gut closure may have residual benefits. Although absorption
will have ceased, immunoglobulins can still provide protection against pathogens in the
GIT [17]. Moreover, there is an abundance of components that can improve calf diarrhea
such as oligosaccharides, lipids, growth factors and hormones antibodies that continue to
protect and maintain a healthy GIT [77,128]. Furthermore, several bioactives in colostrum
provide immunity through phagocytosis and the prevention of pathogen growth [77]. This
abundant combination of nutrients and bioactives could be the resource that is necessary
in the treatment of diarrhea in young calves.
6. Future Research Directions
There have been recent studies attempting to find alternative treatments for neonatal
calf diarrhea, including essential oil, probiotics and prebiotics, most of which have shown
to decrease calf mortality and improve ADG [129–131]. However, the current alternatives
to antimicrobials consist of either a single treatment or a combination of 2–4 ingredients;
contrarily, colostrum is a natural combination of hundreds of bioactives specifically tailored
to an individual calf [77,129,130]. Knowledge is still lacking within this field and minimal
research has been conducted to evaluate the impact natural bovine colostrum can have
as a treatment for neonatal calf diarrhea. It is not known whether colostrum can lead to
improved recovery from diarrheic symptoms or what the proper treatment protocol should
be (i.e., required dosage and quality level of the colostrum). It is clear that an adequate
quantity of colostrum fed quickly after birth will provide the calf with protection against
the development of diarrhea. Additional research has highlighted that, even following
gut closure, supplementation of colostrum can reduce diarrhea through its bioactive and
immune enhancing components [29]. Other research has shown that, by adding colostrum
to milk replacers, the probability that antimicrobial treatment would be required decreased
by 57.7%, as colostrum acted as a protectant against diarrhea, respiratory disease and navel
ill [30].
7. Conclusions
The dairy industry is making tremendous efforts to improve animal welfare and health
through improved hygiene, management and environment. However, several diseases
in pre-weaning calves still pose a serious issue. With antimicrobial resistance steadily
growing, there has been a recent influx in research related to antimicrobial alternatives.
Colostrum holds the potential to be used as a natural prophylactic and therapy for diarrhea
in young calves. Using future research regarding the development of protocols, this therapy
may be a practical and natural method to treat pre-weaning calves with diarrhea while
adhering to industry and consumer standards.
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